ConductScience.org, home

Paper15123775

CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses?

Gumperz JE. J Leukoc Biol, 2004. Cited by 23 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? Papers, record 15123775. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15123775

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses?
PubMed
Journal
J Leukoc Biol
PubMed
Year
2004
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
0.41
iCite
Revised in PubMed
2016-10-19
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gumperz JEJenny E

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antigens, CD1Major topic
Interleukin-12Major topic
Killer Cells, NaturalMajor topic
Myeloid CellsMajor topic
NeoplasmsMajor topic
T-Lymphocyte SubsetsMajor topic
Animals
Antigens, CD1d
Autoantigens
Cytotoxicity, Immunologic
Humans

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 HL071590NHLBI NIH HHSUnited StatesR01HL071590PubMed and NIH
R01 HL 071590-01NHLBI NIH HHSUnited StatesR01HL071590PubMed and NIH

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
38,538,574Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Nat Commun2024https://conductscience.org/library/papers/38538574PubMed
38,105,958Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.medRxiv2023https://conductscience.org/library/papers/38105958PubMed
35,830,292Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA.Blood Adv2022https://conductscience.org/library/papers/35830292PubMed
34,079,772NHS-IL12, a Tumor-Targeting Immunocytokine.Immunotargets Ther2021https://conductscience.org/library/papers/34079772PubMed
30,185,656Induction of antiinflammatory purinergic signaling in activated human iNKT cells.JCI Insight2018https://conductscience.org/library/papers/30185656PubMed
30,131,389First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.Clin Cancer Res2019https://conductscience.org/library/papers/30131389PubMed
21,646,050Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.Clin Immunol2011https://conductscience.org/library/papers/21646050PubMed
21,240,487Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.Cancer Immunol Immunother2011https://conductscience.org/library/papers/21240487PubMed
20,706,692Contribution of gut bacteria to liver pathobiology.Gastroenterol Res Pract2010https://conductscience.org/library/papers/20706692PubMed
20,034,047Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis.Hepatology2010https://conductscience.org/library/papers/20034047PubMed
19,411,762Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.J Clin Invest2009https://conductscience.org/library/papers/19411762PubMed
17,710,228Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.J Clin Invest2007https://conductscience.org/library/papers/17710228PubMed

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD1D912PubTator's text mininghttps://conductscience.org/library/genes/912NCBI Gene
IFNG3,458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL103,586PubTator's text mininghttps://conductscience.org/library/genes/3586NCBI Gene
IL12B3,593PubTator's text mininghttps://conductscience.org/library/genes/3593NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/15123775

GET https://conductscience.org/api/papers/v1/15123775/authors